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ABSTRACT: Streptomyces genomes have a high G + C 
content and typically use an ATG or GTG codon to 
initiate protein synthesis. Although gene-finding tools 
perform well in low GC genomes, it is known that the 
accuracy in predicting a translational start site (TSS) is 
much less for high GC genomes. LipPks1 is a 
Streptomyces-derived, well-characterized modular 
polyketide synthase (PKS). Using this enzyme as a 
model, we experimentally investigated the effects of 
alternative TSSs using a heterologous host, Streptomyces 
venezuelae. One of the TSSs employed boosted the 
protein level by 59-fold and the product yield by 23-fold 
compared to the originally annotated start codon. 
Interestingly, a structural model of the PKS indicated the 
presence of a structural motif in the N-terminus, which 
may explain the observed different protein levels 
together with a proline and arginine-rich sequence that 
may inhibit translational initiation. This structure was 
also found in 6 other modular PKSs that utilize non-
carboxylated starter substrates, which may guide the 
selection of optimal TSSs in conjunction with start-
codon prediction software. 
Natural products, such as polyketides and nonribosomal 
peptides, from the genus Streptomyces have been the 
source of and inspiration for many clinically useful 
antibacterial, anti-tumor, anti-parasitic, and 
immunosuppressive drugs as well as herbicidal and 
insecticidal agents. In fact, over one-third of known 
polyketides and nonribosomal peptides originate from 
this genus.1 Polyketides and nonribosomal peptides are 
produced from very large enzymes that resemble 
modular assembly lines, and which are intrinsically 
capable of creating unique and diverse molecular 
structures.  
    Genome mining is a powerful tool to discover novel 
compounds from sequenced genomes.2, 3 Two related 
strategies have proven successful to identify and 
characterize target biosynthetic gene clusters (BGCs): 
gene knock outs in the native hosts and heterologous 
gene expression in genetically tractable hosts. 
Heterologous expression of modular polyketide synthase 
(PKS) and nonribosomal peptide synthetase (NRPS) 
genes has been demonstrated in various hosts including 
several Streptomyces species (e.g. S. coelicolor, S. albus, 
S. lividans, and S. avermitilis).4, 5 Although these studies 
have significantly contributed to our understanding of 
many BGCs, this strategy is not always successful.  
     Streptomyces genomes have a base composition of 
70% or more G + C and usually use an ATG or GTG 
codon to initiate protein synthesis.6 Although gene-
finding tools perform well in low GC content genomes, 
it is known that the accuracy is much less for high GC 
genomes.7 One possible explanation of the above failure 
is the use of improper start codons in heterologous hosts. 
One may design an expression vector based on a mis-
annotated start codon, which may cause translational 
inhibition and/or produce misfolded, non-functional 
proteins. Translational machinery in a heterologous host 
may select for translational start sites (TSSs) different 
from those used by the native host. Native hosts may 
also have enzymes to post-translationally truncate the N-
terminus of proteins to functionalize them.8 
 Streptomyces venezuelae ATCC 10712 (hereafter 
referred to as S. venezuelae) is an emerging promising 
chassis for heterologous expression of genes derived 
from Streptomyces and closely related genera because of 
its genetic tractability, and relatively rapid doubling 
time, as well as having a complete genome sequence, 
genome engineering/editing tools, several well-
characterized natural/synthetic promoters and ribosomal 
binding sites (RBSs).6, 9-11 The host also contains an 
exceptionally high number of phosphopantetheinyl 
transferases including eight Sfp types,12 which are 
required to convert PKS and NRPS apo proteins to their 
corresponding holo forms. Using S. venezuelae as a 
heterologous host, we investigated the effects of 
alternative TSSs for a Streptomyces-derived, well-
characterized modular PKS, LipPks1, as a test case.  
 
Figure 1. A model PKS system used in this study. (A) 
Proposed model for -lipomycin biosynthesis by the 
lipomysin synthase. (B) Proposed model for 
biosynthesis of 1 by LipPks1+TE. 
    LipPks1 comprises the load and module 1 of the 
lipomycin synthase from Streptomyces aureofaciens Tü117 
(Figure 1A).13 It is composed of a loading didomain 
consisting of an acyltransferase (AT) domain and an acyl 
carrier protein (ACP) domain, and an extension module 
composed of a ketosynthase (KS) domain, an AT domain, a 
ketoreductase (KR) domain, and an ACP domain. As 
annotated in GenBank, translational initiation of the 
lipPks1 gene starts from the proline and arginine-rich 
sequence and produces an approximately 170-residue N-
terminal tail upstream of the catalytically active loading AT 
domain, as shown in Figure 2 
(https://www.ncbi.nlm.nih.gov/nuccore/77864456). In a 
previous study, we constructed an expression vector that 
encodes N-terminal hexahistidine (6xHis)-tagged LipPks1 
with the thioesterase (TE) domain from the erythromycin 
PKS appended to the C-terminus (LipPks1+TE). 
LipPks1+TE produces 3-hydroxy-2,4-dimethylpentanoic 
acid (1) from isobutyryl-CoA and methylmalonyl-CoA in 
the presence of NADPH (Figure 1B). We also constructed 
a vector encoding LipPks1+TE that lacks the 170-residue 
N-terminal tail and a vector that encode LipPks1+TE 
without the N-terminal His tag. Heterologous expression 
analysis of these three genes in Escherichia coli indicated 
that the linker contributed to stable protein folding, at least, 
in this host14 and that the protein cannot be produced in the 
absence of the N-terminal His tag (data not shown). 
 
Figure 2. Amino acid sequence of the loading AT of 
LipPks1 including the 170-residue N-terminal tail, 
which starts from the proline and arginine-rich sequence. 
Red number indicates potential TSSs in the N-terminal 
tail region. The predicted loading AT domain sequence 
is shaded in gray.  
    According to the nucleotide sequence data in GenBank, 
the native lipPks1 gene starts from a GTG (= GTG1) codon. 
To investigate the effect of alternate start codons in the N-
terminal linker region, we inspected the native gene and 
found 6 GTG codons (= GTG2-GTG7) that may be used as 
TSSs but there was no ATG codon (Figure 2, see also 
Table S2). In Streptomyces, several different tools 
including FramePlot, Prodigal, and Glimmer have been 
used to predict open reading frames.7, 15, 16 FramePlot 
predicted GTG1 as a start codon, which is the same start 
codon annotated in GenBank. However, GTG2 was 
predicted as a start codon in both Prodigal and Glimmer. To 
investigate the impact of different TSSs in a heterologous 
host, S. venezuelae, we constructed chromosome 
integration vectors encoding six different N-terminal-
truncated LipPks1+TE variants that are designed to initiate 
translation at one of the six GTG codons, GTG2-GTG7, 
which can be transferred from E. coli 12567 into S. 
 venezuelae. The introduced vector is then site-specifically 
integrated into the S. venezuelae chromosome at the 
Streptomyces phage ΦC31 attachment site mediated by the 
ΦC31 integrase and cognate attP site encoded in each 
integration vector. We also constructed integration vectors 
encoding N-terminal 6xHis-tagged, GTG1-initiated 
LipPks1+TE, which was previously characterized in vitro,14 
GTG1-initiated LipPks1+TE as a positive control, and 
mCherry as a negative control. These genes were placed 
under the well-characterized strong kasO* promoter.10, 11, 17 
Because the vectors encode the apramycin resistant gene, 
apramycin resistant transconjugants were isolated and 
examined. Correct integrations were verified by the 
polymerase chain reaction (PCR) using primers listed in 
Table S1 (see also Figure S1). The sequence of each PCR 
fragment that contained the promoter and each N-terminal 
tail was also confirmed, indicating the correct integration of 
the plasmid into the chromosome in each S. venezuelae 
strain. Each strain was named by the start codon used (see 
Figure 3). 
 
Figure 3. In vivo analysis of engineered S. venezuelae 
strains. (A) Production of 1 from each strain cultured in 
042 medium was measured at 5 days by LC-TOF-MS 
with an authentic standard (n = 4). (B) Relative quantity 
of LipPks1 at day 5 in each strain was determined by 
MRM-LCMS method targeting two LipPks1-derived 
unique peptides (n = 4).  
    Each of the nine recombinant strains was grown in 
medium 042 for 5 days. Medium 042 has previously been 
developed to produce secondary metabolites from 
Streptomyces sp. 1794418 and gave the best titers in our 
experiments among several different media tested (data not 
shown). The culture broth was mixed with an equal volume 
of methanol and filtered. Crude extracts were then analyzed 
by liquid chromatography time-of-flight mass spectrometry 
(LC-TOF-MS). As shown in Figure 3A, all the strains that 
harbored one of the LipPks1+TE variants in the genomes 
produced the expected 1 as a major product but the titers 
varied from strain to strain. The absolute titers were 
determined using the authentic standard.19 These strains 
also produced 3-hydroxy-2,4-dimethylhexanoic acid, 
originating from the use of 2-methylbutyryl-CoA as the 
starter substrate in place of isobutyryl-CoA (Figure S2). 
Their relative production levels were very similar to those 
of 1 (the absolute titers were not quantified). Strain GTG1 
produced 0.6 ± 0.2 mg/L of 1. Interestingly, strain GTG4, 
whose start codon was not predicted by any of gene-finding 
tools used in this study, produced the highest amount of 1 
(13.8 ± 0.5 mg/L). Although there was no predicted start 
site with various gene-finding, it appears that there is a 
reasonable RBS (GGAG) 7 bp prior to the GTG4 start 
codon in the native gene (Table S2). Time course analysis 
of the strain showed almost linear increase in the titer over 
5 days (Figure S3).  
    To explain the difference in product titers, we used the 
following three approaches: proteomics analysis to 
determine protein levels in vivo, in vitro kinetic analysis, 
and structural analysis through homology modeling. To 
compare protein levels of the PKSs in the different S. 
venezuelae strains, we took cell samples at 5 days, 
extracted proteins, digested the proteins using trypsin, and 
analyzed the tryptic digests using liquid chromatography 
triple-quadrupole-time-of-flight mass spectrometer (LC-
QqQ) and targeted two unique PKS-derived peptides. The 
sum peak area of the two peptides was used to represent 
relative quantity of the protein in each strain. The data 
indicate that the protein levels reflected the amounts of 1 
(Figure 3B), which indicates that protein levels are major 
determinants of the product titers. Comparison between 
strains GTG1 and GTG4 revealed a 59-fold difference in 
the protein levels at 5 days (161 ± 60 vs. 9447 ± 2126). 
    We previously determined the kcat (0.053 min-1) and KM 
(2.9 M) for production of 1 from the N-terminal 6xHis-
tagged, GTG1-initiated LipPks1+TE in vitro.14 To 
determine the kinetic parameters for the LipPks1+TE 
variant where GTG4 is the TSS, we expressed the C-
terminally His-tagged protein in E. coli and purified the 
protein using the same protocol. The kcat and KM values for 
production of 1 were 0.026 ± 0.001 min-1 and 1.9 ± 0.1 
M, respectively (Figure S4). These data suggest that the 
strain that encodes N-terminal 6xHis-tagged, GTG1-
initiated LipPks1+TE (N-His-GTG1 strain) produce twice 
the amount of 1 compared to the GTG4 strain if the protein 
levels were the same and substrate concentrations were 
saturated. From the proteomics studies (Figure 3B), we 
determined that 13-fold difference in the protein levels 
between N-His-GTG1 and GTG4 strains. Assuming that 
 the in vitro determined kinetics are reflective of those in 
vivo, one would predict 6.5-fold less production of 1 by the 
N-His-GTG1 strain compared to GTG4 strain, or 
approximately 2 mg/L. The actual titer from N-His-GTG1 
strain was 1.5 ± 0.2 mg/L, which demonstrates a nice 
correlation between the in vitro and in vivo data.  
    To account for the huge difference in protein levels in the 
engineered S. venezuelae strains tested, we analyzed the 
modeled structure of LipPks1 loading AT including the 
170-residue N-terminal tail (Figure 4, Figure S6). 
Interestingly, the model indicates the presence of a 
structure that resembles a subdomain between KS and AT 
domains in four existing KS-AT didomain crystal structures 
(here referred to as KS-AT linker)20-23. The KS-AT linker is 
usually ~100 residues and forms an overall ----- 
fold. This subdomain was previously proposed to partially 
serve as a docking site for an ACP domain in the polyketide 
chain elongation reaction24. It may also stabilize the 
neighboring AT structure to strengthen substrate binding 
(decreased KM) as previously demonstrated in an AT 
domain swapping study.25 This finding may explain the 
unstable folding without the N-terminal tail in the 
aforementioned E. coli study14 and significantly decreased 
protein and the product levels in GTG5-7 strains. The 
location of GTG4 codon is approximately 20 residues 
before this structural motif. The construct that initiated 
protein synthesis from the GTG3 codon resulted in much 
less protein level compared to those that initiated with the 
GTG2 or GTG4 codons. One of the possible explanation is 
that the nascent polypeptide chain may form an inhibitory 
-sheet structure in the ribosomal tunnel but the reason is 
still unclear26. As shown in Figure 2, GTG1 codon give rise 
to a proline and arginine-rich sequence, which is also 
known to inhibit translational initiation27.  
 
Figure 4. Structural model of the loading AT of LipPks1 
including the 170-residue N-terminal tail. Methionine 
and valine residues corresponding to GTG1-7 are shown 
in red.   
    In summary, we have investigated a causal 
relationship between protein production, catalytic 
activity, and TSS in a heterologous host, S. venezuelae, 
using lipPks1 from the lipomycin BGC as a model. 
Importantly, our analysis indicates that the current start 
codon prediction algorithm for Streptomyces was not 
adequate at least for the PKS tested. One important 
finding in our structural analysis was that the KS-AT 
linker-like structure likely exists in the N-terminal tail in 
LipPks1, which has not been experimentally 
characterized in any PKS that contains a loading AT. 
Interestingly, we also found this structural motif in 6 
other PKSs analyzed including the erythromycin PKS 
(Figure S5, see also Table S3). An erythromycin PKS 
mutant that lacks the first 107 residues, which 
corresponds to the entire N-terminal tail region including 
the KS-AT linker-like structure, showed approximately 
20-fold decreased production of erythromycin, which is 
consistent with our data.28. It appears that the N-terminal 
tail of the borrelidin PKS also contains a part of a KS 
structure (Figure S6), which may indicate that the 
loading AT-ACP didomain was evolved from a KS-AT-
ACP tridomain. To date, the only loading AT structure 
solved is the loading AT from the avermectin PKS.29 
Despite it possessing a high degree of sequence 
similarity (~50%) to that of the lipomycin PKS, the 
avermectin loading AT appears to lack this subdomain. 
From a sequence alignment of all loading ATs from 
PKSs in the SBSPKS database 
(http://202.54.249.142/~pksdb/sbspks/master.html), it 
appears that avermectin is anomalous (Figure S7). The 
avermectin loading AT is very well-known for the 
substrate promiscuity30. This may indicate that the 
avermectin PKS evolved the unusual substrate binding 
ability by losing the KS-AT linker-like structure.  
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Supplemental Figures 
 
Figure S1. Genomic PCR analysis. (A) Expected PCR fragments from each strain. (B) 
Comparison between PCR fragments from each strain that contain a part of ΦC31 integrase, 
kasO* promoter, and different sizes of N-terminal tails. Lane 1 = N-His-GTG1; Lane 2 = GTG1; 
Lane 3 = GTG2; Lane 4 = GTG3; Lane 5 = GTG4; Lane 6 = GTG5; Lane 7 = GTG6; Lane 8 = 
GTG7. (C) Genomic PCR data for LipPks1+TE region. Lane 1 = the first PCR fragment (= 1711 
or 1183 bp); Lane 2 = the second PCR fragment (= 2381 bp); Lane 3 = the third PCR fragment 
(= 2477 bp); Lane 4 = the fourth PCR fragment (= 2709 bp) 
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Figure S2. Production of 3-hydroxy-2,4-dimethylhexanoic acid in genomically engineered S. 
venezuelae strains. (A) Proposed model for biosynthesis of 3-hydroxy-2,4-dimethylhexanoic acid 
by LipPks1+TE. (B) Production of 3-hydroxy-2,4-dimethylhexanoic acid from each strain 
cultured in 042 medium was measured at 5 days by LC-TOF (n = 4). Peak areas were used to 
compare the relative production levels.   
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Figure S3. Time course analysis of (A) 3-hydroxy-2,4-dimethylpentanoic acid production (n = 
3), (B) protein production (n = 3), and (C) cell density (estimated by Bradford assay of the cell 
pellets) for N-His-GTG1 and GTG4 strains (n = 3). 
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Figure S4. Initial velocity analysis for GTG4-initiated LipPks1+TE for different starter acyl-CoA 
substrates. Prism (https://www.graphpad.com/) was used to calculate kinetic parameters and 
errors. 
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Figure S5. Structural models of the loading AT domain of eryAI (from the erythromycin PKS), 
aveAI (from the avermectin PKS), borAI (from the borrelidin PKS), cfa6 (from the coronafacic 
acid PKS), lkmAI (from the lankamycin PKS), megAI (from the megalomicin PKS), and plm1 
(from the phoslactomycin PKS).  
 
  
 
There is no valine residue (GTG codon) before its KS-AT linker-like structure. 
 
 
 
KS-AT linker-like structure was not observed. 
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There is a valine residue (GTG codon) before a structural element in the KS domain. Potential 
TSSs are the following. 
 
M1TGSAV2SAPFLQPPEPVS… 
 
 
 
There is a valine residue (GTG codon) before its KS-AT linker-like structure. Potential TSSs are 
the following (shown in red in the structure). 
 
M1CRAWTPTSMNERYGNNLPGSCCALSNRIDWTSPSRSTPSGKKAAVNRFQYFCRS
LPV2TTFT… 
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There is no valine residue (GTG codon) before its KS-AT linker-like structure. 
 
  
 
There is a valine residue (GTG codon) before its KS-AT linker-like structure. Potential TSSs are 
the following (shown in red in the structure). 
 
M1VDV2PDLLGTRTPHPGPLP… 
 
KS-AT linker-like structure
Loading AT
Megalomicin PKS
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There are valine residues (GTG codon) before its KS-AT linker-like structure. Potential TSSs are 
the following (shown in red in the structure). 
 
M1VPSARSRV2V3LLLARTDEEDQPDWDDVPGV4SV5CAPRDSGSIFATAETCLRAD
RPALVVVHDETGGV6AV7ALALETAGAEHYGPLCDDAEERAAQLRALRPRDRTSAL
DATT… 
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Figure S6. A structural model of (A) the loading AT domain of LipPks1 (from the lipomycin 
PKS, green) superimposed on the KS-AT didomain from module 3 of the erythromycin PKS 
(PDB = 2QO3, yellow) and (B) the loading AT domain of borAI (from the borrelidin PKS, blue) 
superimposed on the KS-AT didomain from module 3 of the erythromycin PKS (PDB = 2QO3, 
yellow). 
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Figure S7. A sequence alignment analysis of loading AT domains including N-terminal tails. 
Abbreviations: Lip, lipomycin; Ery, erythromycin; Ave, avermectin; Bor, borrelidin; Cor, 
coronafacic acid; Lan, lanlamycin; Meg, megalomicin; Pho, phoslactomycin. Loading AT 
domain were shown in bold. 
 
Cor      ------------------------------------------------------------ 
Pho      ------------------------------------------------------------ 
Lan      ------------------------------------------------------------ 
Ery      ------------------------------------------------------------ 
Meg      ------------------------------------------------------------ 
Bor      MTGSAVSAPFLQPPEPVSGHSERKSDPVLLVGAGRRARMADAVRAAGAQAGIDPAVLRRT 
Lip      ------------------------------------------------------------ 
Ave      ------------------------------------------------------------ 
                                                                      
 
Cor      ------------------------------------------------------------ 
Pho      -----------------------------------------------------------M 
Lan      ------------------------------------------------------------ 
Ery      ------------------------------------------------------------ 
Meg      ------------------------------------------------------------ 
Bor      RATLITAGSAGAAGRLAAALRLTGATISLDTRETPTLLALHLAAQALRAGDTSYAVVGAE 
Lip      ------------------------------------------------------------ 
Ave      ------------------------------------------------------------ 
                                                                      
 
Cor      -----------------------------------------------------------M 
Pho      VPSARSRVVL--------------LLARTDEEDQPDWDDVPGVSVCAPRDSGSIFATAET 
Lan      ------------------------------------------------------------ 
Ery      ------------------------------------------------------------ 
Meg      ------------------------------------------------------------ 
Bor      LPDGNCALILARQSAATAEGAVPQAIVRTTTADRTTTAD----HAPAPDDHGSPA--REA 
Lip      ------------------------------------MAG----PPPFPRRRGPSG--RRR 
Ave      ------------------------------------------------------------ 
                                                                      
 
Cor      C---RAWTPTSMNERYGN------------NLPGSCCALSNRIDWTSPSRSTPSGKKAAV 
Pho      CLRADRPALVVVHDETGGVAVALALETAGAEHYGPLCDDA---EER-AAQLRALRPRD-- 
Lan      ---------------------------------------------------------MNA 
Ery      ---------------------------------------------------------MAD 
Meg      ---------------------------------------------------------MVD 
Bor      PHATRTLSPGITQAPAEGFPG----------LLATLHDDT---PLR-PTAVTEHGSDATT 
Lip      C--GGRATPGSVRDRTGRRPAAVP---SRAVCAADLCEEN---DDG-SKNVSEHRGSAGG 
Ave      ------------------------------------------------------------ 
                                                                      
 
Cor      NRFQYFCRSLPVTTFTVPLILSDASPAALAATAQRLRAEHETRSFAEWQVFC-----RQQ 
Pho      ----RTSALDATTAGTVPLLLSGRTEAGLRAHAGRLATHLQER--TDISVADAAF--TQA 
Lan      SPLQGENISAATRGAARPWVLSAADDRALRVWARRLLDHLRAH--PESGADGVGAALAHQ 
Ery      LSKLSDSRTAQPGRIVRPWPLSGCNESALRARARQLRAHLDRF--PDAGVEGVGAALAHD 
Meg      VPDLLGTRTPHPGPLPFPWPLCGHNEPELRARARQLHAYLEGI--SEDDVVAVGAALARE 
Bor      VLVLLDQPQDAAPAAPLPWVVSAPHTRALRATAATLAVHLDTT--P-AAPADVAHTLL-- 
Lip      SV-L-----FPRTGTVLPWVLTGPGAAAVRARSEALRTHLRAS--TEWSPAGVGQALLAG 
Ave      ------------------------------------------------------------ 
                                                                      
 
Cor      LTRDHAEYRAAILATDQASLLKGLDMLARGRASRHLVLGRA-----DQLRQPVLVFPGQG 
Pho      TARTLWPHRAMVAVADRDAVVSALRAMAEGRAGDAAVRAGS-----GGPQSAVFVFPGQG 
Lan      DR--RLPRRAVIVGSSRAEILDGLAAVADDRPHPAVARGTA-----AAPAPVTFVFPGQG 
Ery      EQADAGPHRAVVVASSTSELLDGLAAVADGRPHASVVRGVA-----RPSAPVVFVFPGQG 
Meg      TRAQDGPHRAVVVASSVTELTAALAALAQGRPHPSVVRGVA-----RPTAPVVFVLPGQG 
Bor      -TARPDRHRAAVVGADRATLTDGLRALATGGDAPHLVHGTA-----TGSPRPVFVFPGQG 
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Lip      TGAGADTHRAVVLAGDRAQTLNALAALSAGADHPA---VFTSTRADASPAGPVFVFPGQG 
Ave      -----------------------MQRMDGG-EEPRPAAGEVLGVADEADGGVVFVFPGQG 
                                :  :  .                      .:*:**** 
 
Cor      PLWPRMTTRLSATLPSYQQALHRHGDLIEARIGWNPARALAE---GERIERLLRIQPLQF 
Pho      AQWVGMARELAATTPVFRDKLAECARELRPFVDFELDDVLSG---ALPLERVEVIQPALF 
Lan      SQWPGMATELLGESAVFADAIERCAQVFAAESGWSLTEALETAAAPGTVPRVEIVQPALY 
Ery      AQWAGMAGELLGESRVFAAAMDACARAFEPVTDWTLAQVLDS---PEQSRRVEVVQPALF 
Meg      AQWPGMATRLLAESPVFAAAMRACERAFDEVTDWSLTEVLDS---PEHLRRVEVVQPALF 
Bor      SQWPGMAAELLETSEPFHDSVHACADALAEFVDWSVLDVLRQAPDAPPLRRVDVLQPTLW 
Lip      SQWTGMARELLDSAPVFARKLHDCADAFAPYLGHSLLDSVTGAAGGPEPVGADVVQPALF 
Ave      PQWPGMGRELLDASDVFRESVRACEAAFAPYVDWSVEQVLRDSPDAPGLDRVDVVQPTLF 
           *  *  .*      :   :      :    .      :              :**  : 
 
Cor      ALACSLAETWQAFGIEPAAVIGHSVGEAAAAHVGGYLDEASGAALTVLWGETLTAIEGQG 
Pho      AVMVSLAELWRSNGVTPAAVVGHSFGEIAAVTAAGALTVTDGARLVAAVSKALARLQGNG 
Lan      AVSAALTELWRSFGVEPDAVVGHSMGDLAAAHAAGAVTIEDGARAVARWSKELRPLVGKG 
Ery      AVQTSLAALWRSFGVTPDAVVGHSIGELAAAHVCGAAGAADAARAAALWSREMIPLVGNG 
Meg      AVQTSLAALWRSFGVRPDAVLGHSIGELAAAEVCGAVDVEAAARAAALWSREMVPLVGRG 
Bor      ATMVSLAEVWRSYGVEPAAVVGHCCGEIAAAQVAGALDMRDAARLLAHRSRAWLRLVGKG 
Lip      AVMVALTDLWNAAGVAPGALLGHSLGELAAAHVAGVLSLDDSARVVARWSQAQATLAGRG 
Ave      AVMISLAALWRSQGVEPCAVLGHSLGEIAAAHVSGGLSLADAARVVTLWSQAQTTLAGTG 
         *   :*:  *.: *: * *::**. *: **. . *      .*   .  ..    : * * 
 
Cor      GMLSVAAALDDIKPLL-----DDQESLSVAAINAPRSVTLSGTLMALDALQARLTDAGFW 
Pho      EMVAVALPAEQVTALVA----EWDLDLDIAVVNGPGSTVVAGTTESATALLERLRARDVR 
Lan      DMASVELPADLVAPRLA----DWGPDLVLAGINGPRSVLLAGATDAIERCVAELTAEGVR 
Ery      DMAAVALSADEIEPRIA----RWDDDVVLAGVNGPRSVLLTGSPEPVARRVQELSAEGVR 
Meg      DMAAVALSPAELAARVE----RWDDDVVPAGVNGPRSVLLTGAPEPIARRVAELAAQGVR 
Bor      TVISVATSGQDITRRMA----AWPDSVELAALNGPRSVALAGPPDVLDGIVNDLTDQGIH 
Lip      DMVSVLLPADELADLL---DRRWPGRLVVAVENGPGSAVASGDLDAAAELVAHLTAEGIH 
Ave      ALVSVAATPDELLPRIAPWTEDNPARLAVAAVNGPRSTVVSGAREAVADLVADLTAAQVR 
          : :*      :   :          :  *  *.* *.  :*           *    .  
 
Cor      AWRVPGGQVAGHGPQVEPLRDAVTSR-APAKVMDGQIPYYSSVSGGRQNGEHLDVDYWFR 
Pho      ATLLP-IGIAGHSWRMEPAHEYLVQEAAAVRPRVTGIPVYTSTTTDPLDTGGLDAEHWFR 
Lan      ARTIG-VSMAAHSPHMDWVVARVRAALDWFTPGAGAVPLYSSRTGAVLDTRELTAEHWCA 
Ery      AQVIN-VSMAAHSAQVDDIAEGMRSALAWFAPGGSEVPFYASLTGGAVDTRELVADYWRR 
Meg      AQVVN-VSMAAHSAQVDAVAEGMRSALTWFAPGDSDVPYYAGLTGGRLDTRELGADHWPR 
Bor      AKRIPGVDTVGHCSQVEVLRDHLLDVLRPVSPRPAAVPFYSTVDGTERDTTTLDTDYWYL 
Lip      ARRVD-VGLAAHSPHIDAILPRIRADIAPIRAHTPSIPVYSALHGGALDGTPMDAAYWCR 
Ave      TRMIP-VDVPAHSPLMYAIEERVVSGLLPITPRPSRIPFHSSVTGGRLDTRELDAAYWYR 
         :  :      .*   :      :             :* ::       :   : . :*   
 
Cor      VLRETVRFQDSLQALIADGHRLFIEVSPHPVLTSLIDEALRGAGVVGG-----AVATLDQ 
Pho      SLREPARFQQVIEELLGRGHRVFVEMSPHPVLTLPIEETAAHLG-----RDVVVLDTMRR 
Lan      NFRGRVEFERSVRDCTAERGGVFLELSPHPVLAAAVRQTLDAAG-----SGHPVLATLRR 
Ery      SFRLPVRFDEAIRSALEVGPGTFVEASPHPVLAAALQQTLDAEG-----SSAAVVPTLQR 
Meg      SFRLPVRFDEATRAVLELQPGTFIESSPHPVLAASLQQTLDEVG-----SPAAIVPTLQR 
Bor      NTRSQVRFHQAVRNLLAAGHRSFVEVSPHPLLGASIEDTAAEFG----LDDVAAVGTLRR 
Lip      NLRSTVRFADATRAALEAGHTTFVEVSPHPVLTTAMEVSA-----TRAAHAATVLGTLRR 
Ave      NMSSTVRFEPAARLLLQQGPKTFVEMSPHPVLTMGLQELAPDLGDTTGTADTVIMGTLRR 
              ..*    .         *:* ****:*   :                  : *: : 
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Supplemental Tables 
 
Table S1. Primers used in genomic PCR experiments in Figure S1. 
 
Primer name Target Primer sequence 
SY398 (Forward primer) Amplify 1183-1711 bp 
fragment 
CACTCGACAAGTTCGTTGCGGAA 
SY333 (Reverse primer) Amplify 1183-1711 bp 
fragment 
GTAGCCTGCGCTTGGCTCCA 
SY67 (Forward primer) Amplify 2381 bp fragment TGGACTCCGCACCGGTTTTCG 
SY513 (Reverse primer) Amplify 2381 bp fragment AGAACCCAACCACAACGGGC 
SY70 (Forward primer) Amplify 2477 bp fragment AGCGATGCGCGTCGTCTGG 
SY514 (Reverse primer) Amplify 2477 bp fragment GTAACCATCCACAGCGGTGCA 
SY73 (Forward primer) Amplify 2709 bp fragment GTTACCGCACCGCCTTTAAACG 
SY332 (Reverse primer) Amplify 2709 bp fragment AGCTGTGCTTCCTGTTCGGCT 
 
Table S2. Native gene sequence of the N-terminal tail of LipPks1. GTG4 codon and the potential 
ribosomal binding site were shown in bold. 
 
PKS name Gene sequence 
Lipomycin PKS GTGGCGGGGCCTCCGCCGTTCCCCCGACGGCGGGGGCCCAGCGGCCGTCGGCGGTGCGGCGGAC
GGGCCACCCCCGGATCCGTGCGTGACCGGACCGGGCGGCGCCCGGCCGCCGTGCCGTCACGGGC
CGTCTGTGCCGCAGACCTTTGTGAAGAGAACGACGACGGGAGCAAGAACGTGTCCGAACACCGT
GGCAGTGCAGGCGGCTCCGTACTGTTCCCCCGGACGGGGACCGTGCTGCCCTGGGTCCTGACCG
GTCCCGGCGCCGCCGCCGTGCGGGCCCGTTCCGAGGCTCTGCGCACGCATCTCCGCGCGAGCAC 
CGAATGGTCGCCGGCCGGCGTCGGACAGGCCCTCCTCGCCGGGACTGGAGCCGGGGCGGACACC
CACCGGGCCGTCGTACTCGCCGGGGACCGCGCGCAGACCCTGAACGCGCTCGCCGCGCTGTCCG
CCGGCGCCGACCACCCGGCGGTGTTCACCAGCACCCGCGCGGACGCCTCCCCCGCGGGGCCG 
 
Table S3. Amino acid sequences used in structural modeling in Figure 4 and Figure S5. 
 
PKS name Amino acid sequence 
Lipomycin PKS MAGPPPFPRRRGPSGRRRCGGRATPGSVRDRTGRRPAAVPSRAVCAADLCEENDDGSKNVSEHR
GSAGGSVLFPRTGTVLPWVLTGPGAAAVRARSEALRTHLRASTEWSPAGVGQALLAGTGAGADT
HRAVVLAGDRAQTLNALAALSAGADHPAVFTSTRADASPAGPVFVFPGQGSQWTGMARELLDSA
PVFARKLHDCADAFAPYLGHSLLDSVTGAAGGPEPVGADVVQPALFAVMVALTDLWNAAGVAPG
ALLGHSLGELAAAHVAGVLSLDDSARVVARWSQAQATLAGRGDMVSVLLPADELADLLDRRWPG
RLVVAVENGPGSAVASGDLDAAAELVAHLTAEGIHARRVDVGLAAHSPHIDAILPRIRADIAPI
RAHTPSIPVYSALHGGALDGTPMDAAYWCRNLRSTVRFADATRAALEAGHTTFVEVSPHPVLTT
AMEVSATRAAHAATVLGTLRRGEG 
Erythromycin PKS MADLSKLSDSRTAQPGRIVRPWPLSGCNESALRARARQLRAHLDRFPDAGVEGVGAALAHDEQA
DAGPHRAVVVASSTSELLDGLAAVADGRPHASVVRGVARPSAPVVFVFPGQGAQWAGMAGELLG
ESRVFAAAMDACARAFEPVTDWTLAQVLDSPEQSRRVEVVQPALFAVQTSLAALWRSFGVTPDA
VVGHSIGELAAAHVCGAAGAADAARAAALWSREMIPLVGNGDMAAVALSADEIEPRIARWDDDV
VLAGVNGPRSVLLTGSPEPVARRVQELSAEGVRAQVINVSMAAHSAQVDDIAEGMRSALAWFAP
GGSEVPFYASLTGGAVDTRELVADYWRRSFRLPVRFDEAIRSALEVGPGTFVEASPHPVLAAAL
QQTLDAEGSSAAVVPTLQRGQG 
Avermectin PKS MQRMDGGEEPRPAAGEVLGVADEADGGVVFVFPGQGPQWPGMGRELLDASDVFRESVRACEAAFAPYVDWS
VEQVLRDSPDAPGLDRVDVVQPTLFAVMISLAALWRSQGVEPCAVLGHSLGEIAAAHVSGGLSLADAARVV
TLWSQAQTTLAGTGALVSVAATPDELLPRIAPWTEDNPARLAVAAVNGPRSTVVSGAREAVADLVADLTAA
QVRTRMIPVDVPAHSPLMYAIEERVVSGLLPITPRPSRIPFHSSVTGGRLDTRELDAAYWYRNMSSTVRFE
PAARLLLQQGPKTFVEMSPHPVLTMGLQELAPDLGDTTGTADTVIMGTLRRGQG 
Borrelidin PKS MTGSAVSAPFLQPPEPVSGHSERKSDPVLLVGAGRRARMADAVRAAGAQAGIDPAVLRRTRATL
ITAGSAGAAGRLAAALRLTGATISLDTRETPTLLALHLAAQALRAGDTSYAVVGAELPDGNCAL
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ILARQSAATAEGAVPQAIVRTTTADRTTTADHAPAPDDHGSPAREAPHATRTLSPGITQAPAEG
FPGLLATLHDDTPLRPTAVTEHGSDATTVLVLLDQPQDAAPAAPLPWVVSAPHTRALRATAATL
AVHLDTTPAAPADVAHTLLTARPDRHRAAVVGADRATLTDGLRALATGGDAPHLVHGTATGSPR
PVFVFPGQGSQWPGMAAELLETSEPFHDSVHACADALAEFVDWSVLDVLRQAPDAPPLRRVDVL
QPTLWATMVSLAEVWRSYGVEPAAVVGHCCGEIAAAQVAGALDMRDAARLLAHRSRAWLRLVGK
GTVISVATSGQDITRRMAAWPDSVELAALNGPRSVALAGPPDVLDGIVNDLTDQGIHAKRIPGV
DTVGHCSQVEVLRDHLLDVLRPVSPRPAAVPFYSTVDGTERDTTTLDTDYWYLNTRSQVRFHQA
VRNLLAAGHRSFVEVSPHPLLGASIEDTAAEFGLDDVAAVGTLRRGQG 
Coronafacic acid PKS MCRAWTPTSMNERYGNNLPGSCCALSNRIDWTSPSRSTPSGKKAAVNRFQYFCRSLPVTTFTVPLILSDAS
PAALAATAQRLRAEHETRSFAEWQVFCRQQLTRDHAEYRAAILATDQASLLKGLDMLARGRASRHLVLGRA
DQLRQPVLVFPGQGPLWPRMTTRLSATLPSYQQALHRHGDLIEARIGWNPARALAEGERIERLLRIQPLQF
ALACSLAETWQAFGIEPAAVIGHSVGEAAAAHVGGYLDEASGAALTVLWGETLTAIEGQGGMLSVAAALDD
IKPLLDDQESLSVAAINAPRSVTLSGTLMALDALQARLTDAGFWAWRVPGGQVAGHGPQVEPLRDAVTSRA
PAKVMDGQIPYYSSVSGGRQNGEHLDVDYWFRVLRETVRFQDSLQALIADGHRLFIEVSPHPVLTSLIDEA
LRGAGVVGGAVATLDQRKDD 
Lankamycin PKS MNASPLQGENISAATRGAARPWVLSAADDRALRVWARRLLDHLRAHPESGADGVGAALAHQDRR
LPRRAVIVGSSRAEILDGLAAVADDRPHPAVARGTAAAPAPVTFVFPGQGSQWPGMATELLGES
AVFADAIERCAQVFAAESGWSLTEALETAAAPGTVPRVEIVQPALYAVSAALTELWRSFGVEPD
AVVGHSMGDLAAAHAAGAVTIEDGARAVARWSKELRPLVGKGDMASVELPADLVAPRLADWGPD
LVLAGINGPRSVLLAGATDAIERCVAELTAEGVRARTIGVSMAAHSPHMDWVVARVRAALDWFT
PGAGAVPLYSSRTGAVLDTRELTAEHWCANFRGRVEFERSVRDCTAERGGVFLELSPHPVLAAA
VRQTLDAAGSGHPVLATLRRGQG 
Megalomicin PKS MVDVPDLLGTRTPHPGPLPFPWPLCGHNEPELRARARQLHAYLEGISEDDVVAVGAALARETRAQDGPHRA
VVVASSVTELTAALAALAQGRPHPSVVRGVARPTAPVVFVLPGQGAQWPGMATRLLAESPVFAAAMRACER
AFDEVTDWSLTEVLDSPEHLRRVEVVQPALFAVQTSLAALWRSFGVRPDAVLGHSIGELAAAEVCGAVDVE
AAARAAALWSREMVPLVGRGDMAAVALSPAELAARVERWDDDVVPAGVNGPRSVLLTGAPEPIARRVAELA
AQGVRAQVVNVSMAAHSAQVDAVAEGMRSALTWFAPGDSDVPYYAGLTGGRLDTRELGADHWPRSFRLPVR
FDEATRAVLELQPGTFIESSPHPVLAASLQQTLDEVGSPAAIVPTLQRDQG 
Phoslactomycin PKS MVPSARSRVVLLLARTDEEDQPDWDDVPGVSVCAPRDSGSIFATAETCLRADRPALVVVHDETGGVAVALA
LETAGAEHYGPLCDDAEERAAQLRALRPRDRTSALDATTAGTVPLLLSGRTEAGLRAHAGRLATHLQERTD
ISVADAAFTQATARTLWPHRAMVAVADRDAVVSALRAMAEGRAGDAAVRAGSGGPQSAVFVFPGQGAQWVG
MARELAATTPVFRDKLAECARELRPFVDFELDDVLSGALPLERVEVIQPALFAVMVSLAELWRSNGVTPAA
VVGHSFGEIAAVTAAGALTVTDGARLVAAVSKALARLQGNGEMVAVALPAEQVTALVAEWDLDLDIAVVNG
PGSTVVAGTTESATALLERLRARDVRATLLPIGIAGHSWRMEPAHEYLVQEAAAVRPRVTGIPVYTSTTTD
PLDTGGLDAEHWFRSLREPARFQQVIEELLGRGHRVFVEMSPHPVLTLPIEETAAHLGRDVVVLDTMRRD 
 
Table S4. Plasmids used in this study 
 
Plasmid Summary Source or reference 
pSY169 (JPUB_TBD) 
kasOp*-GTG1-started 
LipPks1+TE 
This study 
pSY170 (JPUB_TBD) 
kasOp*-GTG2-started 
LipPks1+TE 
This study 
pSY171 (JPUB_TBD) 
kasOp*-GTG3-started 
LipPks1+TE 
This study 
pSY172 (JPUB_TBD) 
kasOp*-GTG4-started 
LipPks1+TE 
This study 
pSY173 (JPUB_TBD) 
kasOp*-GTG5-started 
LipPks1+TE 
This study 
pSY174 (JPUB_TBD 
kasOp*-GTG6-started 
LipPks1+TE 
This study 
pSY175 (JPUB_TBD) 
kasOp*-GTG7-started 
LipPks1+TE 
This study 
pSY196 (JPUB_009552) 
T7p-GTG4-started 
LipPks1+TE-His 
This study 
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Plasmid 22 (JPUB_009550) kasOp*-mCherry This study 
Plasmid 34  (JPUB_TBD) 
kasOp*-His-GTG1-started 
LipPks1+TE 
This study 
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Supplemental Methods 
 
Chemicals. All chemicals were purchased from Sigma-Aldrich unless otherwise described.  
 
Plasmids. Gene fragments that encode LipPks1+TE or the variants were PCR-amplified from 
pSY0741 and subcloned into a slightly modified Streptomyces Integration Vector that encodes 
ΦC31 integrase and kasO* promoter2 using NdeI and EcoRI to generate pSY169-pSY175 and 
plasmid 34. mCherry gene was also subcloned into the same vector (Plasmid 22). To express 
GTG4-started LipPks1+TE in E. coli, the corresponding gene was subcloned into pET30 vector 
(pSY196). Plasmids used in this study are listed in Table S4. The plasmids along with their 
associated information have been deposited in the public version of JBEI registry (http://public-
registry.jbei.org) and are physically available from the authors upon request.  
 
Conjugal transfer of vectors to S. venezuelae. E. coli ET12567/pUZ8002 was transformed 
with an appropriate vector and selected for on LB agar containing apramycin (50 g/mL). A 
single colony was used to inoculate a 5 mL of LB containing kanamycin (25 g/mL), 
chloramphenicol (15 g/mL), and apramycin (25 g/mL) at 37°C. The overnight culture was 
used to seed 10 mL of LB containing the same antibiotics, which was grown at 37°C to an OD600 
of 0.4-0.6. The E. coli cells were pelleted by centrifugation, washed twice with LB, and 
resuspended in 500 L of LB. Fresh S. venezuelae spores were collected from a glycerol-
arginine plate with 5 mL of 2xYT and incubated at 50°C for 10 min. The spores (500 L) and 
the E. coli cells (500 L) were mixed, spread onto mannitol soy agar, and incubated at 23°C for 
16-20 h. After addition of nalidixic acid (20 g/mL) and apramycin (40 g/mL) were added, the 
plate was further incubated for 3-4 days. A single colony was used to inoculate into TSB 
containing nalidixic acid (25 g/mL) and apramycin (25 g/mL). Following overnight 
incubation, the culture was spread onto a glycerol-arginine plate. The plate was incubated for 2-3 
days. The spores were collected from the plate with 3-4 mL of water and mixed with glycerol to 
prepare 25% glycerol stock. The glycerol stock was stored at -80°C. 
 
Polyketide production. Engineered S. venezuelae spores were grown in 5 mL of TSB medium 
containing nalidixic acid (50 g/mL) and apramycin (50 g/mL) for 1-2 days at 30°C. The 
overnight culture was used to seed 5 mL of 042 containing the same antibiotics, which was 
grown at 30°C for overnight. 3% of the overnight culture was then used to inoculate 30 mL of 
042 medium containing the same antibiotics, which was grown for 2-5 days at 30°C. 300 μl of 
supernatants were collected from the culture, mixed with 300 μl of methanol, and then incubated 
at 50°C for overnight (the tube was covered with parafilm). The resulting solution was cooled 
down at 4°C, centrifuged, and filtered using Amicon Ultra Centrifugal filters, 3 kDa Ultracel, 0.5 
mL device (Millipore). The flow-through was analyzed by LC-TOF MS. 
  
 
Polyketide detection. LC separation of 3-hydroxycarboxylic acids was conducted on a Kinetex 
XB-C18 column (100-mm length, 3.0-mm internal diameter, and 2.6-μm particle size; 
Phenomenex, Torrance, CA USA) using an Agilent Technologies 1200 Series Rapid Resolution 
HPLC system (Agilent Technologies, Santa Clara, CA, USA). A sample injection volume of 3 
μL was used. The sample tray and column compartment were set to 6 and 50°C, respectively. 
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The mobile phase was composed of 0.1% formic acid (Sigma-Aldrich, St. Louis, MO, USA) in 
water (A) and 0.1% formic acid in methanol (B). 3-hydroxycarboxylic acids were separated 
using the following gradient: linearly increased from 5% to 72.1% B in 6.5 min, further 
increased to 95% B in 1.3 min, held at 95 % for 1 min, decreased from 95% to 5% B in 0.4 min, 
and held at 5% B for 2 min. The flow rate was held at 0.42 mL/min for 8.8 min, linearly 
increased from 0.42 mL/min to 0.65 mL/min in 0.4 min, and held at 0.65 mL/min for 2 min. The 
total LC run time was 11.2 min. The HPLC system was coupled to an Agilent Technologies 6210 
series time-of-flight mass spectrometer (TOF-MS). Drying and nebulizing gases were set to 11 
L/min and 30 lb/in2, respectively, and a drying-gas temperature of 330°C was used throughout. 
MS detection of [M – H]– ions was conducted in the negative ion mode via electrospray 
ionization. A capillary voltage of 3,500 V was used throughout. The fragmentor, skimmer, and 
OCT 1 RF Vpp voltages were set to 150, 50, and 170 V, respectively. The acquisition range was 
from 95-1000 m/z, and the acquisition rate was 0.86 spectra/sec. The TOF-MS was tuned with 
the Agilent ESI-L Low concentration tuning mix in the range of 50-1700 m/z. Data acquisition 
and processing were conducted by Agilent MassHunter Workstation and Agilent MassHunter 
Profinder, respectively. 
 
Proteomics. Engineered S. venezuelae strains were grown in 042 medium for 5 days. The cells 
were harvested by centrifugation. Protein extraction from E. coli cell pellets were accomplished 
using a chloroform/methanol precipitation method as previously described3. Briefly, cell pellets 
were resuspended in 400 μl of methanol and briefly vortexed, followed by sequential additions of 
100 μl of chloroform and 300 μl of water with short intervals of vortexing in between. Phase 
separation was achieved by centrifugation at 14,000 rpm for 1 minutes. The methanol/water 
layer was removed and 300 μl of methanol was added afterwards. The protein was pellet after 
another centrifugation, and the supernatant was decanted. The resulted protein was resuspended 
in 100 mM ammonium bicarbonate buffer supplemented with 20% methanol and urea at final 
concentration of 3 M. Protein concentration was determined by the DC assay (BioRad, Hercules, 
CA). Proteins were then reduced 5 mM tris 2-(carboxyethyl) phosphine for 30 min at room 
temperature, and alkylated with 10 mM iodoacetamide for 30 min at room temperature in the 
dark. Proteins were digested overnight at a final concentration of 1 mg/mL with trypsin at a 1:50 
trypsin: total protein ratio. The resulted tryptic peptides were subjected to LCMS analysis. All 
SRM methods development and assays were performed on an Agilent 6460 QQQ mass 
spectrometer system coupled with an Agilent 1290 UHPLC system (Agilent Technologies). A 
Sigma–Aldrich Ascentis Peptides ES-C18 column (2.1 mm × 50 mm, 2.0 μm particle size, 
operated at 60) was used to separate peptides at 0.400 mL/min standard flow rate. The mobile 
phase was composed of 0.1% formic acid in water (solvent A) and 0.1% formic acid in 
acetonitrile (solvent B). Peptides were separated using the following gradient: 5% to 35% B for 
20 min, followed by a short ramp up to 80% B and held for 1 min, and then ramped down to 5% 
B and re-equilibrate the column. Peptides were introduced to the mass spectrometer from LC and 
ionized by using an Agilent Jet Stream source (Agilent Technologies) operating in positive-ion 
mode with the following parameter settings: Sheath Gas flow=11 l/min, Sheath Gas 
Temperature=350C, Nozzle Voltage=1000 V, Nebulizing Pressure=30 psi, Chamber 
Voltage=4500 V. The targeted MRM method and acquired data were public available in 
panorama website under the following project link: https://goo.gl/8fHMvX. 
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Protein purification. An E. coli K207-3 strain4 harboring pSY196 was grown in LB medium 
supplemented with appropriate antibiotics at 37°C until the OD600 reached 0.4-0.6. The cultures 
were then cooled to 18°C and induced with 250 M isopropyl-β-D-galactopyranoside for 16-18 
h. The cells were harvested by centrifugation and resuspended in lysis/wash buffer (50 mM 
phosphate, pH 7.6, 300 mM sodium chloride, 10 mM imidazole, 4°C). The cells were lysed by 
sonication, and cellular debris was removed by centrifugation. Nickel-NTA agarose resin 
(Qiagen) was added directly to the supernatant (10 mL of resin slurry per L of culture) and 
mixed for 1 h at 4°C. The resulting mixture was poured into a fritted column, washed with 10 
resin volumes of lysis/wash buffer (4°C), and eluted with 2 resin volumes of elution buffer (150 
mM phosphate, pH 7.6, 50 mM sodium chloride, 150 mM imidazole, 4°C). The eluted protein 
was then applied to a HiTRAP Q anion exchange column (GE Healthcare), washed with 5 resin 
volumes of wash buffer (50 mM phosphate, pH 7.6, 200 mM sodium chloride, 8% glycerol, 4°C), 
and eluted at approximately 375 mM sodium chloride. The fractions containing target PKSs were 
concentrated using an Amicon Ultra-15 Centrifugal Filter, 100K device (Millipore). The 
resulting purified protein was stored at -80°C. 
 
Enzyme kinetics. 3-Hydroxycarboxylic acid production was carried out in 100 mM phosphate 
buffer, pH 7.2, containing 2.5 mM TCEP at 23°C in the presence of 0.5 M GTG4-started 
LipPks1+TE, various concentrations of starter acyl-CoA substrates (propionyl-CoA, butyryl-
CoA, isobutyryl-CoA, 2-methylbutyryl-CoA, and isovaleryl-CoA), 200 M of methylmalonyl-
CoA and 500 M NADPH. The reactions were quenched at different time points by adding an 
equal volume of methanol and centrifuged. The supernatants were then analyzed by LC-MS. 
Initial velocity at each concentration of substrate was determined by analyzing 3 different time 
points (n = 1). 
 
Structural modeling. Amino acid sequences used in structural modeling are listed in Table S2. 
I-TASSER (https://zhanglab.ccmb.med.umich.edu/) was used to generate all tertiary structure 
models. The internal C-score scoring function in I-TASSER was utilized to select the best 
homology models for each amino acid sequence used in Figure 4, Figure S5, and Figure S6. 
 
Multiple sequence alignment. Amino acid sequences listed in Table S2 are analyzed by Clustal 
Omega (http://www.ebi.ac.uk/Tools/msa/clustalo/).  
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